Philip A Watson
Pulmonary and Respiratory Medicine · 2009–2017
A researcher in the Science corpus: 4 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Pulmonary and Respiratory Medicine — 47 citations into it
Whom Philip A Watson trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from Philip A Watson's perspective
Ordered by how strongly the researchers Philip A Watson trusts endorse each paper. Same corpus, a different order for every researcher.
- Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. (Journal of Clinical Oncology)
- A Novel Androgen Receptor Splice Variant Is Upregulated during Prostate Cancer Progression and Promotes Androgen-depletion-resistant Growth (Cancer Research)
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study (The Lancet)
- Molecular determinants of resistance to antiandrogen therapy (Nature Medicine)
- Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer (Nature)
- Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. (Cancer Cell)
- STAR: ultrafast universal RNA-seq aligner (Bioinform.)
- Myc-driven murine prostate cancer shares molecular features with human prostate tumors. (Cancer Cell)
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples (Nature Biotechnology)
- A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. (Molecules and Cells)
Their papers
- SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer (2017) — 945 citations
- Emerging Mechanisms of Resistance to Androgen Receptor Inhibitors in Prostate Cancer (2015) — 1,370 citations
- Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor (2010) — 650 citations
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer (2009) — 2,232 citations